Cargando…

Metastatic renal carcinoma comprehensive prognostic system

The purpose of the study was to identify a comprehensive prognostic system of pretreatment clinical parameters in 425 patients (pts) with metastatic renal-cell carcinoma treated with different subcutaneous (s.c.) recombinant cytokine-based home therapies in consecutive trials. Treatment consisted of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Atzpodien, J, Royston, P, Wandert, T, Reitz, M
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2003
Materias:	Clinical
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2747541/ https://www.ncbi.nlm.nih.gov/pubmed/12569375 http://dx.doi.org/10.1038/sj.bjc.6600768

Ejemplares similares

An approach to estimating prognosis using fractional polynomials in metastatic renal carcinoma
por: Royston, P, et al.
Publicado: (2006)

Rapid deterioration in quality of life during interleukin-2- and α-interferon-based home therapy of renal cell carcinoma is associated with a good outcome
por: Atzpodien, J, et al.
Publicado: (2003)

Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: Results of a prospectively randomised Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN)
por: Atzpodien, J, et al.
Publicado: (2005)

IL-2 in combination with IFN-αand 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial
por: Atzpodien, J, et al.
Publicado: (2001)

Interleukin 10 (IL-10): an immunosuppressive factor and independent predictor in patients with metastatic renal cell carcinoma
por: Wittke, F, et al.
Publicado: (1999)

Is treatment with interferon-α effective in all patients with metastatic renal carcinoma? A new approach to the investigation of interactions
por: Royston, P, et al.
Publicado: (2004)

Cisplatin, gemcitabine, and treosulfan in relapsed stage IV cutaneous malignant melanoma patients
por: Atzpodien, J, et al.
Publicado: (2007)

Prognostic impact of in vivo soluble cell adhesion molecules in metastatic renal cell carcinoma
por: Hoffmann, R, et al.
Publicado: (1999)

Capecitabine in the treatment of metastatic renal cell carcinoma
por: Oevermann, K, et al.
Publicado: (2000)

Prognostic factors in metastatic renal cell carcinoma: metastasectomy as independent prognostic variable
por: Vogl, U M, et al.
Publicado: (2006)

Interleukin-2/interferon-α2a/13-retinoic acid-based chemoimmunotherapy in advanced renal cell carcinoma: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN)
por: Atzpodien, J, et al.
Publicado: (2006)

Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma
por: Motzer, R J, et al.
Publicado: (2013)

A Comprehensive Prognostic Stratification for Patients with Metastatic Renal Clear Cell Carcinoma
por: Cho, Kang Su, et al.
Publicado: (2008)

Prognostic factors for survival in patients with metastatic renal cell carcinoma treated with targeted therapies
por: Procopio, G, et al.
Publicado: (2012)

Baseline quality of life as a prognostic survival tool in patients receiving sunitinib for metastatic renal cell carcinoma
por: Cella, D, et al.
Publicado: (2012)

Comprehensive Systematic Review of Biomarkers in Metastatic Renal Cell Carcinoma: Predictors, Prognostics, and Therapeutic Monitoring
por: Dani, Komal A., et al.
Publicado: (2023)

Metastatic renal cell carcinoma in the thyroid gland
por: Cruz, Mark M., et al.
Publicado: (2020)

Development and validation of a prognostic model in patients with metastatic renal cell carcinoma treated with sunitinib: a European collaboration
por: Bamias, A, et al.
Publicado: (2013)

Combination chemotherapy with or without s.c. IL-2 and IFN-α: results of a prospectively randomized trial of the Cooperative Advanced Malignant Melanoma Chemoimmunotherapy Group (ACIMM)
por: Atzpodien, J, et al.
Publicado: (2002)

Metastatic renal cell carcinoma presenting with melena
por: Sadhale, Ashwini, et al.
Publicado: (2018)

Phase II clinical trial of capecitabine and gemcitabine chemotherapy in patients with metastatic renal carcinoma
por: Waters, J S, et al.
Publicado: (2004)

Phase II trial of the antiangiogenic agent IM862 in metastatic renal cell carcinoma
por: Deplanque, G, et al.
Publicado: (2004)

Buccodental side effects of sunitinib in patients with metastatic renal cell carcinoma
por: Gilabert, M, et al.
Publicado: (2013)

Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma
por: Hutson, T E, et al.
Publicado: (2014)

Safety and efficacy of subcutaneous and continuous intravenous infusion rIL-2 in patients with metastatic renal cell carcinoma
por: Geertsen, P F, et al.
Publicado: (2004)

A Comprehensive Overview of Targeted Therapy in Metastatic Renal Cell Carcinoma
por: Mihály, Z, et al.
Publicado: (2012)

Characterizing the outcomes of metastatic papillary renal cell carcinoma
por: Connor Wells, John, et al.
Publicado: (2017)

Survival and clinical prognostic factors in metastatic non‐clear cell renal cell carcinoma treated with targeted therapy: A multi‐institutional, retrospective study using the Korean metastatic renal cell carcinoma registry
por: Kim, Jung Kwon, et al.
Publicado: (2019)

Immunotherapy in Metastatic Renal Cell Carcinoma: A Comprehensive Review
por: Raman, Rachna, et al.
Publicado: (2015)

Complete metastasectomy in renal cell carcinoma: a propensity-score matched by the International Metastatic RCC Database Consortium prognostic model
por: Fares, Aline F, et al.
Publicado: (2019)

Proximal humerus pathological fracture due to metastatic renal cell carcinoma
por: Aravind, M., et al.
Publicado: (2020)

Tumour shrinkage measured with first treatment evaluation under VEGF-targeted therapy as prognostic marker in metastatic renal cell carcinoma (mRCC)
por: Seidel, C, et al.
Publicado: (2013)

Prognostic significance of the dynamic changes of systemic inflammatory response in metastatic renal cell carcinoma
por: Wang, Beihe, et al.
Publicado: (2019)

Targeting the Endothelin Axis with Atrasentan, in combination with IFN-alpha, in metastatic renal cell carcinoma
por: Groenewegen, G, et al.
Publicado: (2012)

Concomitant Drugs Prognostic Score in Patients With Metastatic Renal Cell Carcinoma Receiving Ipilimumab and Nivolumab in the Compassionate Use Program in Italy: Brief Communication
por: Buti, Sebastiano, et al.
Publicado: (2023)

Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine: clinical findings
por: Jonasch, E, et al.
Publicado: (2008)

Circulating cytokines associated with clinical response to systemic therapy in metastatic renal cell carcinoma
por: Chehrazi-Raffle, Alexander, et al.
Publicado: (2021)

Maxillary Sinus Vascular Malformation or Metastatic Renal Cell Carcinoma: The Importance of Differential Diagnosis
por: Shah, Harsh R., et al.
Publicado: (2021)

Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma
por: Gore, M E, et al.
Publicado: (2015)

Construction and validation of a novel prognostic nomogram for patients with metastatic renal cell carcinoma: a SEER-based study
por: Lu, Zhaoxiang, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_e401an5r95jmi57d24fdlfkq0v